Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 41

1.

Phosphodiesterase Type 5 (PDE5) Inhibitors.

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.
2017 Aug 2.

2.
3.

Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction.

Corbin JD, Francis SH, Webb DJ.

Urology. 2002 Sep;60(2 Suppl 2):4-11. Review.

PMID:
12414329
4.

Overview of phosphodiesterase 5 inhibition in erectile dysfunction.

Rosen RC, Kostis JB.

Am J Cardiol. 2003 Nov 6;92(9A):9M-18M. Review.

PMID:
14609619
5.

Phosphodiesterase type 5 inhibitors as a treatment for erectile dysfunction: Current information and new horizons.

Ferguson JE 3rd, Carson CC 3rd.

Arab J Urol. 2013 Sep;11(3):222-9. doi: 10.1016/j.aju.2013.07.009. Epub 2013 Sep 18. Review.

6.

New treatment options for erectile dysfunction in patients with diabetes mellitus.

Basu A, Ryder RE.

Drugs. 2004;64(23):2667-88. Review.

PMID:
15537369
7.

Tadalafil.

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.
2017 Aug 2.

8.
9.

Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction.

Goldenberg MM.

Clin Ther. 1998 Nov-Dec;20(6):1033-48. Review.

PMID:
9916601
10.

Molecular mechanisms that could contribute to prolonged effectiveness of PDE5 inhibitors to improve erectile function.

Francis SH, Morris GZ, Corbin JD.

Int J Impot Res. 2008 Jul-Aug;20(4):333-42. doi: 10.1038/ijir.2008.4. Epub 2008 Apr 17. Review.

PMID:
18418391
11.

Molecular pharmacotherapeutic targeting of PDE5 for preservation of penile health.

Burnett AL.

J Androl. 2008 Jan-Feb;29(1):3-14. Epub 2007 Oct 17. Review.

12.
13.

Comparison of phosphodiesterase type 5 (PDE5) inhibitors.

Wright PJ.

Int J Clin Pract. 2006 Aug;60(8):967-75. Epub 2006 Jun 16. Review. Erratum in: Int J Clin Pract. 2006 Nov;60(11):1517.

PMID:
16780568
14.

Overall cardiovascular profile of sildenafil citrate.

Zusman RM, Morales A, Glasser DB, Osterloh IH.

Am J Cardiol. 1999 Mar 4;83(5A):35C-44C. Review.

PMID:
10078541
15.

Clinical monograph for drug formulary review: erectile dysfunction agents.

Campbell HE.

J Manag Care Pharm. 2005 Mar;11(2):151-71. Review.

16.

[Medication of the month. Vardenafil (Levitra)].

Scheen AJ.

Rev Med Liege. 2003 Sep;58(9):576-9. Review. French.

17.

Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease.

Ravipati G, McClung JA, Aronow WS, Peterson SJ, Frishman WH.

Cardiol Rev. 2007 Mar-Apr;15(2):76-86. Review.

PMID:
17303994
18.

Mechanisms of action of PDE5 inhibition in erectile dysfunction.

Corbin JD.

Int J Impot Res. 2004 Jun;16 Suppl 1:S4-7. Review.

PMID:
15224127
19.

Structure -activity relationships of PDE5 inhibitors.

Eros D, Szántai-Kis C, Kiss R, Kéri G, Hegymegi-Barakonyi B, Kövesdi I, Orfi L.

Curr Med Chem. 2008;15(16):1570-85. Review.

PMID:
18673225
20.

PDE5 inhibitors: in vitro and in vivo pharmacological profile.

Kouvelas D, Goulas A, Papazisis G, Sardeli C, Pourzitaki C.

Curr Pharm Des. 2009;15(30):3464-75. Review.

PMID:
19860692

Supplemental Content

Support Center